Renal Pericytes as a Target for Angiotensin II Signaling in Hypertension
肾周细胞作为高血压血管紧张素 II 信号传导的靶标
基本信息
- 批准号:10654833
- 负责人:
- 金额:$ 12.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Angiotensin IIAngiotensin II ReceptorAngiotensin ReceptorAngiotensinsAnimalsAttenuatedAutomobile DrivingBioinformaticsBiologyBiomedical ResearchBlood PressureBlood VesselsBlood capillariesBlood flowCellsChronic Kidney FailureCoalCoupledData SetDevelopmentDiameterDrug TargetingFluorescence-Activated Cell SortingFunctional disorderGTP-Binding ProteinsGene TargetingGeneticGenetic TranscriptionGlomerular Filtration RateHealthHeart failureHumanHypertensionImageInfusion proceduresInjury to KidneyKidneyKidney DiseasesKnockout MiceKnowledgeLinkMeasuresMediatingMentorsMentorshipMicrosurgeryMolecularMolecular BiologyMusMyofibroblastNatriuresisNephrologyOpticsOregonPathogenicityPathologicPathologyPathway interactionsPeptidesPericytesPhysiologyPlayPopulationPopulation DistributionsPrincipal InvestigatorProcessPublicationsPublishingReceptor, Angiotensin, Type 1Renal Blood FlowRenal HypertensionRenal functionRenin-Angiotensin SystemResearchResearch PersonnelResearch ProposalsResistanceRoleScienceSignal TransductionSliceSortingSystemic blood pressureTechniquesTestingTissuesTrainingUniversitiesVascular DiseasesVascular Morphologic Changeblood pressure controlblood pressure elevationblood pressure regulationcareercareer developmentcell typecomparison controldecubitus ulcerdefined contributiondesignexperimental studyhypertension treatmentin vivokidney vascular structureknockout animalnext generationnovelnovel therapeuticspharmacologicprogramsreceptorrenin hypertensionsingle cell analysissingle-cell RNA sequencingskillstooltranscriptional reprogrammingvasoconstriction
项目摘要
PROJECT SUMMARY
The renin-angiotensin-system (RAS) plays a central role in regulating systemic blood pressure. This is illustrated
by the proven benefit of RAS-targeted drugs such as angiotensin receptor blockers, which are critical to the
treatment of hypertension, heart failure and kidney disease. The actions of the RAS depend on the peptide
angiotensin II (ang II) acting on cells that express the G-protein coupled type 1 angiotensin receptor (human:
AT1; mouse: AT1a). Our group has been at the forefront of unmasking cell-specific roles of ang II signaling
within different cell populations in the kidney. These studies have revealed novel roles for ang II to act distinctly
in different cell types to drive pathogenic mechanisms associated with hypertension. This suggests that the
overall, systemic effect of ang II on blood pressure results from the cumulative actions of ang II on multiple cell
types within the body. Our preliminary studies analyzed recently published single-cell RNA Sequencing datasets
to explore the cell-specific expression of angiotensin receptors within the kidney. We find that pericytes, a mural
cell type associated with capillaries and the glomerulus, express the mouse AT1a receptor. Additionally, we
confirmed this by measuring AT1a expression from rapidly sorted pericytes from the kidney. However, the role
of angiotensin signaling in pericytes remains under-examined. This is despite multiple lines of evidence that
suggest renal pericytes play a central role in regulating blood pressure and renal injury, angiotensin-linked
processes which are pathologically altered in hypertension and chronic kidney disease. This project will test the
overall hypothesis that angiotensin II signaling within pericytes contributes to the development of hypertension
and renal injury. This candidate has developed a novel mouse line which has inducible pericyte-specific deletion
of the AT1a receptor. First, the contribution of pericyte ang II signaling to blood pressure control will be
determined under baseline conditions and during ang II hypertension. Next, the effect of ang II signaling within
pericytes on renal injury in the context of hypertension will be assessed. This research will be carried out by an
applicant with excellent training in biomedical research with a strong publication record. The training for this
proposal will occur at Oregon Health & Science University within the Division of Nephrology and Hypertension
under the primary mentorship of Dr. Susan Gurley a leader in the field of cell-specific actions of RAS signaling
in the kidney. This project will also be supported by two other co-mentors: Dr. Anusha Mishra, an expert on
pericyte biology and microvascular blood flow, and Dr. Lynne Sakai, an expert on vascular fibrotic signaling.
Career development activities include training in mouse micro-surgery, ex vivo slice imaging, assessment of
renal pathology, and bioinformatic analysis of single-cell RNA sequencing datasets. This training is designed to
launch the candidate to lead the next generation of kidney research with well-honed skills in animal physiology
and molecular biology. This will setup the candidate to meet his long-term career coal of becoming an
independent investigator focusing on the cellular and molecular causes of hypertension and renal injury.
项目总结
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Advances in use of mouse models to study the renin-angiotensin system.
- DOI:10.1016/j.mce.2021.111255
- 发表时间:2021-06-01
- 期刊:
- 影响因子:4.1
- 作者:Emathinger, Jacqueline M.;Nelson, Jonathan W.;Gurley, Susan B.
- 通讯作者:Gurley, Susan B.
Soluble ACE2 Is Filtered into the Urine.
可溶性 ACE2 被过滤到尿液中。
- DOI:10.34067/kid.0001622022
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Nelson,JonathanW;Ortiz-Melo,DavidI;Mattocks,NatalieK;Emathinger,JacquelineM;Prescott,Jessica;Xu,Katherine;Griffiths,RobertC;Wakasaki,Rumie;Piehowski,PaulD;Hutchens,MichaelP;Coffman,ThomasM;Gurley,SusanB
- 通讯作者:Gurley,SusanB
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan W Nelson其他文献
Jonathan W Nelson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan W Nelson', 18)}}的其他基金
Renal Pericytes as a Target for Angiotensin II Signaling in Hypertension
肾周细胞作为高血压血管紧张素 II 信号传导的靶标
- 批准号:
10431802 - 财政年份:2020
- 资助金额:
$ 12.75万 - 项目类别:
Renal Pericytes as a Target for Angiotensin II Signaling in Hypertension
肾周细胞作为高血压血管紧张素 II 信号传导的靶标
- 批准号:
9975374 - 财政年份:2020
- 资助金额:
$ 12.75万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 12.75万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 12.75万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 12.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 12.75万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 12.75万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 12.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 12.75万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 12.75万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 12.75万 - 项目类别: